Skip to main content
. 2009 Jan 31;3(3):238–247. doi: 10.1016/j.molonc.2009.01.003

Figure 2.

Figure 2

Flow cytometric analysis of antibodies. The five monospecific antibodies Ab–D1, Ab–D2, Ab–D3, Ab–D4 and Ab–5, were subjected to flow cytometric analysis to screen for potential binding to native HER2 on the cell surface of the ductal carcinoma cell line BT474. Cell binding ability was evaluated for all five monospecific antibodies as well as two commercially available monoclonal antibodies (Trastuzumab/Pertuzumab) and one negative control (Ab–intra) targeting an inaccessible intracellular part of HER2.